Literature DB >> 19203586

PH domain-only protein PHLDA3 is a p53-regulated repressor of Akt.

Tatsuya Kawase1, Rieko Ohki, Tatsuhiro Shibata, Shuichi Tsutsumi, Naoko Kamimura, Johji Inazawa, Tsutomu Ohta, Hitoshi Ichikawa, Hiroyuki Aburatani, Fumio Tashiro, Yoichi Taya.   

Abstract

p53 And Akt are critical players regulating tumorigenesis with opposite effects: whereas p53 transactivates target genes to exert its function as a tumor suppressor, Akt phosphorylates its substrates and transduces downstream survival signals. In addition, p53 and Akt negatively regulate each other to balance survival and death signals within a cell. We now identify PHLDA3 as a p53 target gene that encodes a PH domain-only protein. We find that PHLDA3 competes with the PH domain of Akt for binding of membrane lipids, thereby inhibiting Akt translocation to the cellular membrane and activation. Ablation of endogenous PHLDA3 results in enhanced Akt activity and decrease of p53-dependent apoptosis. We also demonstrate the suppression of anchorage-independent cell growth by PHLDA3. Loss of the PHLDA3 genomic locus was frequently observed in primary lung cancers, suggesting a role of PHLDA3 in tumor suppression. Our results reveal a new mode of coordination between the p53 and Akt pathways.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19203586     DOI: 10.1016/j.cell.2008.12.002

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  100 in total

1.  Quantitative proteomics analysis reveals molecular networks regulated by epidermal growth factor receptor level in head and neck cancer.

Authors:  Wei Yang; Quan Cai; Vivian W Y Lui; Patrick A Everley; Jayoung Kim; Neil Bhola; Kelly M Quesnelle; Bruce R Zetter; Hanno Steen; Michael R Freeman; Jennifer R Grandis
Journal:  J Proteome Res       Date:  2010-06-04       Impact factor: 4.466

2.  Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer.

Authors:  Sherry X Yang; Joseph P Costantino; Chungyeul Kim; Eleftherios P Mamounas; Dat Nguyen; Jong-Hyeon Jeong; Norman Wolmark; Kelley Kidwell; Soonmyung Paik; Sandra M Swain
Journal:  J Clin Oncol       Date:  2010-05-17       Impact factor: 44.544

3.  Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression.

Authors:  Colleen A Brady; Dadi Jiang; Stephano S Mello; Thomas M Johnson; Lesley A Jarvis; Margaret M Kozak; Daniela Kenzelmann Broz; Shashwati Basak; Eunice J Park; Margaret E McLaughlin; Anthony N Karnezis; Laura D Attardi
Journal:  Cell       Date:  2011-05-13       Impact factor: 41.582

4.  PHLDA3 is a novel tumor suppressor of pancreatic neuroendocrine tumors.

Authors:  Rieko Ohki; Kozue Saito; Yu Chen; Tatsuya Kawase; Nobuyoshi Hiraoka; Raira Saigawa; Maiko Minegishi; Yukie Aita; Goichi Yanai; Hiroko Shimizu; Shinichi Yachida; Naoaki Sakata; Ryuichiro Doi; Tomoo Kosuge; Kazuaki Shimada; Benjamin Tycko; Toshihiko Tsukada; Yae Kanai; Shoichiro Sumi; Hideo Namiki; Yoichi Taya; Tatsuhiro Shibata; Hitoshi Nakagama
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-27       Impact factor: 11.205

5.  Serine/threonine kinase 17A is a novel p53 target gene and modulator of cisplatin toxicity and reactive oxygen species in testicular cancer cells.

Authors:  Pingping Mao; Mary P Hever; Lynne M Niemaszyk; Jessica M Haghkerdar; Esty G Yanco; Damayanti Desai; Maroun J Beyrouthy; Joanna S Kerley-Hamilton; Sarah J Freemantle; Michael J Spinella
Journal:  J Biol Chem       Date:  2011-04-13       Impact factor: 5.157

6.  PHLPP-1 negatively regulates Akt activity and survival in the heart.

Authors:  Shigeki Miyamoto; Nicole H Purcell; Jeffrey M Smith; Tianyan Gao; Ross Whittaker; Katherine Huang; Rene Castillo; Chris C Glembotski; Mark A Sussman; Alexandra C Newton; Joan Heller Brown
Journal:  Circ Res       Date:  2010-06-24       Impact factor: 17.367

7.  Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics.

Authors:  Le Su; Arthur V Sampaio; Kevin B Jones; Marina Pacheco; Angela Goytain; Shujun Lin; Neal Poulin; Lin Yi; Fabio M Rossi; Juergen Kast; Mario R Capecchi; T Michael Underhill; Torsten O Nielsen
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

8.  Transcriptionally inducible Pleckstrin homology-like domain, family A, member 1, attenuates ErbB receptor activity by inhibiting receptor oligomerization.

Authors:  Shigeyuki Magi; Kazunari Iwamoto; Noriko Yumoto; Michio Hiroshima; Takeshi Nagashima; Rieko Ohki; Amaya Garcia-Munoz; Natalia Volinsky; Alexander Von Kriegsheim; Yasushi Sako; Koichi Takahashi; Shuhei Kimura; Boris N Kholodenko; Mariko Okada-Hatakeyama
Journal:  J Biol Chem       Date:  2017-12-12       Impact factor: 5.157

9.  Function, regulation and pathological roles of the Gab/DOS docking proteins.

Authors:  Franziska U Wöhrle; Roger J Daly; Tilman Brummer
Journal:  Cell Commun Signal       Date:  2009-09-08       Impact factor: 5.712

10.  Histone deacetylase 3 depletion in osteo/chondroprogenitor cells decreases bone density and increases marrow fat.

Authors:  David F Razidlo; Tiffany J Whitney; Michelle E Casper; Meghan E McGee-Lawrence; Bridget A Stensgard; Xiaodong Li; Frank J Secreto; Sarah K Knutson; Scott W Hiebert; Jennifer J Westendorf
Journal:  PLoS One       Date:  2010-07-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.